Developing an antibody-binding protein cage as a molecular recognition drug modular nanoplatform

Biomaterials

Volumn 33, Issue 21, 2012, Pages 5423-5430

  Kang, Hyo Jin ^a,b   Kang, Young Ji ^c   Lee, Young Mi ^a,b   Shin, Hyun Hee ^c   Chung, Sang J ^a,b   Kang, Sebyung ^c  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

^c Ulsan National Institute of Science and Technology   (South Korea)

Author keywords

Antibody binding; Delivery platform; Fc binding peptide; Molecular recognition; Protein cages

Indexed keywords

ANTIBODY-BINDING; BREAST CANCER; BREAST CANCER CELLS; DELIVERY PLATFORM; FC REGION; FLUORESCENT CELLS; FOLATE RECEPTOR; FOUR-FOLD SYMMETRY; NON-COVALENT COMPLEXES; PROTEIN CAGES; SELF-ASSEMBLED; SPECIFIC BINDING; TARGETED DELIVERY; TRASTUZUMAB;

MOLECULAR IMAGING; MONOCLONAL ANTIBODIES; PEPTIDES;

MOLECULAR RECOGNITION;

ANTIBODY BINDING PROTEIN; BINDING PROTEIN; FC BINDING PEPTIDE; FERRITIN; FOLATE RECEPTOR; IMMUNOGLOBULIN G; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONJUGATION; FLUORESCENCE IMAGING; FLUORESCENCE MICROSCOPY; MOLECULAR PROBE; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUARTZ CRYSTAL MICROBALANCE; SURFACE PLASMON RESONANCE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; CARRIER PROTEINS; CELL LINE, TUMOR; CHROMATOGRAPHY, GEL; DRUG DELIVERY SYSTEMS; HUMANS; MICROSCOPY, FLUORESCENCE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NANOPARTICLES; NANOTECHNOLOGY; PEPTIDES; QUARTZ CRYSTAL MICROBALANCE TECHNIQUES; RABBITS;

ORYCTOLAGUS CUNICULUS;

EID: 84860920261     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.03.055     Document Type: Article

References (44)

1. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
2. Vasir J.K., Reddy M.K., Labhasetwar V.D. Nanosystems in drug targeting: opportunities and challenges. Curr Nanosci 2005, 1:47-64.
3. Peer D., Karp J.M., Hong S., FaroKhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
4. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3:16-20.
5. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4:145-160.
6. Zamboni W.C. Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res 2005, 11:8230-8234.
7. Bartlett D.W., Su H., Hildebrandt I.J., Weber W.A., Davis M.E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 2007, 104:15549-15554.
8. Lee E.S., Na K., Bae Y.H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release 2005, 103:405-418.
9. Lee E.S., Na K., Bae Y.H. Super pH-sensitive multifunctional polymeric micelle. Nano Lett 2005, 5:325-329.
10. Sutton D., Nasongkla N., Blanco E., Gao J.M. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res 2007, 24:1029-1046.
11. Couvreur P., Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res 2006, 23:1417-1450.
12. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284.
13. Gillies E.R., Frechet J.M.J. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today 2005, 10:35-43.
14. Brigger I., Dubernet C., Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002, 54:631-651.
15. Hirsch L.R., Gobin A.M., Lowery A.R., Tam F., Drezek R.A., Halas N.J., et al. Metal nanoshells. Ann Biomed Eng 2006, 34:15-22.
16. Hong S., Leroueil P.R., Majoros I.J., Orr B.G., Baker J.R., Holl M.M.B. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem Biol 2007, 14:107-115.
17. Shi D.L., Bedford N.M., Cho H.S. Engineered multifunctional nanocarriers for cancer diagnosis and therapeutics. Small 2011, 7:2549-2567.
18. Erathodiyil N., Ying J.Y. Functionalization of inorganic nanoparticles for bioimaging applications. Acc Chem Res 2011, 44:925-935.
19. Hainfeld J.F. Uranium-loaded apoferritin with antibodies attached: molecular design for uranium neutron-capture therapy. Proc Natl Acad Sci USA 1992, 89:11064-11068.
20. Douglas T., Young M. Viruses: making friends with old foes. Science 2006, 312:873-875.
21. Lewis J.D., Destito G., Zijlstra A., Gonzalez M.J., Quigley J.P., Manchester M., et al. Viral nanoparticles as tools for intravital vascular imaging. Nat Med 2006, 12:354-360.
22. Kang S., Lander G.C., Johnson J.E., Prevelige P.E. Development of bacteriophage P22 as a platform for molecular display: Genetic and chemical modifications of the procapsid exterior surface. Chembiochem 2008, 9:514-518.
23. Strable E., Finn M.G. Chemical modification of viruses and virus-like particles. Curr Top Microbiol Immunol 2009, 327:1-21.
24. Tong G.J., Hsiao S.C., Carrico Z.M., Francis M.B. Viral capsid DNA aptamer conjugates as multivalent cell-targeting vehicles. J Am Chem Soc 2009, 131:11174-11178.
25. Kang S., Uchida M., O'Neil A., Li R., Prevelige P.E., Douglas T. Implementation of P22 viral capsids as nanoplatforms. Biomacromolecules 2010, 11:2804-2809.
26. Ashley C.E., Carnes E.C., Phillips G.K., Durfee P.N., Buley M.D., Lino C.A., et al. Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles. ACS Nano 2011, 5:5729-5745.
27. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001, 1:118-129.
28. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002, 2:750-763.
29. von Mehren M., Adams G.P., Weiner L.M. Monoclonal antibody therapy for cancer. Annu Rev Med 2003, 54:343-369.
30. Jølck R., Feldborg L., Andersen S., Moghimi S., Andresen T. Engineering liposomes and nanoparticles for biological targeting, biofunctionalization of polymers and their applications 2011, 251-280. Springer, Berlin / Heidelberg. G.S. Nyanhongo, W. Steiner, G. Gübitz (Eds.).
31. Biju V., Itoh T., Ishikawa M. Delivering quantum dots to cells: bioconjugated quantum dots for targeted and nonspecific extracellular and intracellular imaging. Chem Soc Rev 2010, 39:3031-3056.
32. Manjappa A.S., Chaudhari K.R., Venkataraju M.P., Dantuluri P., Nanda B., Sidda C., et al. Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J Control Release 2011, 150:2-22.
33. Danczyk R., Krieder B., North A., Webster T., HogenEsch H., Rundell A. Comparison of antibody functionality using different immobilization methods. Biotechnol Bioeng 2003, 84:215-223.
34. Gao J., Gu H., Xu B. Multifunctional magnetic nanoparticles: design, synthesis, and biomedical applications. Acc Chem Res 2009, 42:1097-1107.
35. Bonroy K., Frederix F., Reekmans G., Dewolf E., De Palma R., Borghs G., et al. Comparison of random and oriented immobilisation of antibody fragments on mixed self-assembled monolayers. J Immunol Methods 2006, 312:167-181.
36. DeLano W.L., Ultsch M.H., de Vos A.M., Wells J.A. Convergent solutions to binding at a protein-pr otein interface. Science 2000, 287:1279-1283.
37. Jung Y.W., Kang H.J., Lee J.M., Jung S.O., Yun W.S., Chung S.J., et al. Controlled antibody immobilization onto immunoanalytical platforms by synthetic peptide. Anal Biochem 2008, 374:99-105.
38. Tatur J., Hagen W.R., Matias P.M. Crystal structure of the ferritin from the hyperthermophilic archaeal anaerobe Pyrococcus furiosus. J Biol Inorg Chem 2007, 12:615-630.
39. Kang Y.J., Uchida M., Shin H.-H., Douglas T., Kang S. Biomimetic FePt nanoparticle synthesis within Pyrococcus furiosus ferritins and their layer-by-layer formation. Soft Matter 2011.
40. Jeong Y.J., Kang H.J., Bae K.H., Kim M.G., Chung S.J. Efficient selection of IgG Fc domain-binding peptides fused to fluorescent protein using E. coli expression system and dot-blotting assay. Peptides 2010, 31:202-206.
41. Kang S., Suci P.A., Broomell C.C., Iwahori K., Kobayashi M., Yamashita I., et al. Janus-like protein cages. Spatially controlled dual-functional surface modifications of protein cages. Nano Lett 2009, 9:2360-2366.
42. Rhodes A. Developing a cell line standard for HER2/neu. Cancer Biomark 2005, 1:229-232.
43. Carney W.P., Neumann R., Lipton A., Leitzel K., Ali S., Price C.P. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clin Breast Cancer 2004, 5:105-116.
44. Hellstrom I., Goodman G., Pullman J., Yang Y., Hellstrom K.E. Overexpression of HER-2 in ovarian carcinomas. Cancer Res 2001, 61:2420-2423.